COMP <GO>
SMMT vs ASND // 10Y YIELD & FRED MACRO BETA
Summit Therapeutics Inc. (NASDAQ) VS. Ascendis Pharma A/S Ordinary Share (NASDAQ) • 15-METRIC TALLY: SMMT 1
— ASND 10
▲ 10Y YIELD & FRED MACRO BETA LEADER: ASND
LAST: $16.03 (-1.05%) • MKT CAP: $12.82B
macro-sensitivity
0.97
LAST: $251.27 (-0.68%) • MKT CAP: $16.55B
macro-sensitivity
0.98
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SMMT VS. ASND)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SMMT | ASND | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 9.90% | -44.90 | ASND | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 21.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.50% | 2.21% | -4.71 | ASND | /fcf-yield <GO> |
| Operating Margin | -36.30% | 13.90% | -50.20 | ASND | /operating-margins <GO> |
| Net Profit Margin | -29.80% | 10.90% | -40.70 | ASND | /net-margins <GO> |
| Revenue Growth (YoY) | 11.00% | 12.10% | -1.10 | ASND | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.74 | +22.26 | SMMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | ASND | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.5 | 63.3 | -12.80 | ASND | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.97 | 0.98 | -0.01 | ASND | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 27.6x | +6.40 | ASND | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.82B | $16.55B | -$3.74B | ASND | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SMMT REV | ASND REV | SMMT GROSS % | ASND GROSS % | SMMT FCF | ASND FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$323.6M | — |
| FY 2024 | $0 | — | — | — | -$142.2M | — |
| FY 2023 | $0 | — | — | — | -$76.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SMMT // BETA 0.97
ASND // BETA 0.98